Biologics News

Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

FDA · IgA Nephropathy · 4 min

Outlook Therapeutics Resubmits LYTENAVA BLA to FDA, Initiating 60-Day Review

FDA · 5 min

IPEC Excipient World Biologics Summit 2026: Recap

general · 3 min

Clinical Outsourcing Trends 2026: Key Takeaways for Pharma

general · 8 min

ReDI 2026: FDA Regulatory Strategies Conference Recap

general · 5 min

FDA's REdI Conference 2026: Regulatory Strategies & Insights

regulatory · 3 min

EpiBiologics Begins Phase 1 Trial of EPI-326 Bispecific Antibody for EGFR-Driven Cancers

2 min